CMS Explains “Newness” Criterion In Blincyto NTAP Discontinuation
Amgen’s argument that continuing the Medicare new technology add-on payment for Blincyto would allow for more data to be collected failed to persuade US CMS.
You may also be interested in...
CMS agrees to provide new technology add-on payments for Amgen’s cancer drug for acute lymphoblastic leukemia after the company documents Blincyto’s uniqueness and its advantages over existing treatments.
There may be significant savings from eliminating wasteful packaging for high cost specialty drugs. The US FDA, however, is urging policy makers not to overlook the importance of patient safety in packaging issues.
CMS streamlined process for enhanced payments is having an impact: seven antibiotic applications for New Technology Add-On Payment status in 2021—including one for a product that has been marketed for more than five years.